Use of azithromycin and risk of ventricular arrhythmia

CMAJ

Volumn 189, Issue 15, 2017, Pages E560-E568

  Trifirò, Gianluca ^a,b   De Ridder, Maria ^a   Sultana, Janet ^a,c   Oteri, Alessandro ^a   Rijnbeek, Peter ^a   Pecchioli, Serena ^d   Mazzaglia, Giampiero ^d   Bezemer, Irene ^e   Garbe, Edeltraut ^f   Schink, Tania ^f   Poluzzi, Elisabetta ^g   Frøslev, Trine ^h   Molokhia, Mariam ⁱ   Diemberger, Igor ^g   Sturkenboom, Miriam C J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d Health Search Italian College of General Practitioners   (Italy)

^e PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^f LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG USE; FEMALE; HEART DEATH; HEART VENTRICLE ARRHYTHMIA; HIGH RISK BEHAVIOR; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; RISK ASSESSMENT; RISK FACTOR; CASE CONTROL STUDY; CHEMICALLY INDUCED; HEART ARRHYTHMIA; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ARRHYTHMIAS, CARDIAC; AZITHROMYCIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 85018467666     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.160355     Document Type: Article

References (35)

1. Vogt AW, Zollo RA. Long Q-T syndrome associated with oral erythromycin used in preoperative bowel preparation. Anesth Analg 1997; 85: 1011-3.
2. Tschida SJ, Guay DR, Straka RJ, et al. QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: a prospective evaluation and review of theliterature. Pharmacotherapy 1996; 16: 663-74.
3. De Ponti F, Poluzzi E, Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol 2000; 56: 1-18.
4. Drici MD, Knollmann BC, Wang WX, et al. Cardiac actions of erythromycin: influence of female sex. JAMA 1998; 280: 1774-6.
5. Shafer D, Singer S, Korvick J, et al. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis 2002; 35: 197-200.
6. Koh TW Risk of torsades de pointes from oral erythromycin with concomitant carbimazole (methimazole) administration. Pacing Clin Electrophysiol 2001; 24: 1575-6.
7. Matsunaga N, Oki Y, Prigollini A. A case of QT-interval prolongation precipitated by azithromycin. N Z Med J 2003; 116: U666.
8. Samarendra P, Kumari S, Evans SJ, et al. QT prolongation associated with azithromycin/amiodarone combination. Pacing Clin Electrophysiol 2001; 24: 1572-4.
9. Russo V, Puzio G, Siniscalchi N. Azithromycin-induced QT prolongation in elderly patient. Acta Biomed 2006; 77: 30-2.
10. Arellano-Rodrigo E, García A, Mont L, et al. Torsade de pointes and cardiorespiratory arrest induced by azithromycin in a patient with congenital long QT syndrome [article in Spanish]. Med Clin (Barc) 2001; 117: 118-9.
11. Kezerashvili A, Khattak H, Barsky A, et al. Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors. J Interv Card Electrophysiol 2007; 18: 243-6.
12. Huang BH, Wu CH, Hsia CP, et al. Azithromycin-induced torsade de pointes. Pacing Clin Electrophysiol 2007; 30: 1579-82.
13. Kim MH, Berkowitz C, Trohman RG. Polymorphic ventricular tachycardia with a normal QT interval following azithromycin. Pacing Clin Electrophysiol 2005; 28: 1221-2.
14. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366: 1881-90.
15. FDA statement regarding azithromycin (Zithromax) and the risk of cardiovascular death. Silver Spring (MD): US Food and Drug Administration; 2012. Available: www.fda.gov/Drugs/DrugSafety/ucm304372.htm (accessed 2015 June 24).
16. Svanström H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med 2013; 368: 1704-12.
17. Rao GA, Mann JR, Shoaibi A, et al. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam Med 2014; 12: 121-7.
18. Hinkle LE Jr, Thaler HT. Clinical classification of cardiac deaths. Circulation 1982; 65: 457-64.
19. Marcus FI, Cobb LA, Edwards JE, et al. Mechanism of death and prevalence of myocardial ischemic symptoms in the terminal event afer acute myocardial infarction. Am J Cardiol 1988; 61: 8-15.
20. Mortensen EM, Halm EA, Pugh MJ, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA 2014; 311: 2199-208.
21. Trac MH, McArthur E, Jandoc R, et al. Macrolide antibiotics and the risk of ventricular arrhythmia in older adults. CMAJ 2016; 188: E120-9.
22. Chou HW, Wang JL, Chang CH, et al. Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study. Clin Infect Dis 2015; 60: 566-77.
23. Molokhia M, De Ponti F, Behr ER, et al. Academic output from EU-funded health research projects [letter]. Lancet 2012; 380: 1903-4.
24. Avillach P, Coloma PM, Gini R, et al. Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project. J Am Med Inform Assoc 2013; 20: 184-92.
25. Mor A, Frøslev T, Thomsen RW, et al. Antibiotic use varies substantially among adults: a cross-national study from five European countries in the ARITMO project. Infection 2015; 43: 453-72.
26. Diemberger I, Oteri A, Rijnbeek P, et al. Epidemiology of ventricular arrhythmias in five European countries [abstract submitted to World Congress in Cardiac Electrophysiology and Cardiac Techniques, June 18-21, 2014 - Nice France. Europace 2014; 16(Suppl 2).
27. CredibleMeds [homepage]. Available: https://crediblemeds.org (accessed 2014 Jan. 15).
28. Coloma PM, Schuemie MJ, Trifirò G, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf 2011; 20: 1-11.
29. Trifirò G, Coloma PM, Rijnbeek PR, et al. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: Why and how? J Intern Med 2014; 275: 551-61.
30. Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of randomefects meta-analysis. J R Stat Soc Ser A Stat Soc 2009; 172: 137-59.
31. Ohara H, Nakamura Y, Watanabe Y, et al. Azithromycin can prolong QT interval and suppress ventricular contraction, but will not induce Torsade de Pointes. Cardiovasc Toxicol 2015; 15: 232-40.
32. Nakajima T, Kaneko Y, Kurabayashi M. Unveiling specific triggers and precipitating factors for fatal cardiac events in inherited arrhythmia syndromes. Circ J 2015; 79: 1185-92.
33. Pasquié JL, Sanders P, Hocini M, et al. Fever as a precipitant of idiopathic ventricular fibrillation in patients with normal hearts. J Cardiovasc Electrophysiol 2004; 15: 1271-6.
34. Hernández-Díaz S, García Rodríguez LA. Nonsteroidal anti-inflammatory drugs and risk of lung cancer. Int J Cancer 2007; 120: 1565-72.
35. García Rodríguez LA, Cea Soriano L, Hill C, et al. Increased risk of stroke afer discontinuation of acetylsalicylic acid: a UK primary care study. Neurology 2011; 76: 740-6.